Business News
Lilly’s cancer therapy Lartruvo fails study, shares drop
Eli Lilly said on Friday its cancer treatment Lartruvo, approved on an accelerated basis in 2016, failed to improve patient survival in a long-term study and will no longer be prescribed, driving shares down 3 […]